VISTAGEN THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $10.05 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-06-30 was $10.05, a 7.03% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-06-30 was $9.39, a 71.07% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-06-30 was $32.46.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2026 was $2.81, a 92.21% decline from fiscal 2025.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $36.09, a 87.29% increase from fiscal 2024.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $19.27, a 54.44% decline from fiscal 2023.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $42.30, a 29.15% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $10.05 10-Q · filed 2026-08-14 | ||||
| 2026-03-31 | $2.81 10-K · filed 2026-06-15 | ||||
| 2025-12-31 | $2.55 10-Q · filed 2026-02-12 | ||||
| 2025-09-30 | $9.39 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | $9.39 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | $36.09 10-K · filed 2025-06-17 | ||||
| 2024-12-31 | $36.09 10-Q · filed 2025-02-13 | ||||
| 2024-09-30 | $31.18 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $32.46 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | $19.27 10-K · filed 2024-06-11 | ||||
| 2023-03-31 | $42.30 10-K · filed 2023-06-28 | ||||
| 2022-03-31 | $59.70 10-K · filed 2023-06-28 | $1.99 10-K · filed 2022-06-23 | |||
| 2021-03-31 | $0.00 10-K · filed 2022-06-23 | ||||
| 2020-03-31 | $0.00 10-K · filed 2021-06-29 | ||||
| 2019-03-31 | $0.00 10-K · filed 2020-06-29 | ||||
| 2018-03-31 | $5.39 10-K · filed 2019-06-25 | ||||
| 2017-03-31 | $0.00 10-K · filed 2018-06-26 | ||||
| 2016-03-31 | $9.26 10-K · filed 2017-06-29 | ||||
| 2015-03-31 | $9.25 10-K · filed 2016-06-24 | ||||
| 2014-03-31 | $27.22 10-K · filed 2015-06-29 | $1.75 10-K · filed 2014-06-25 | |||
| 2013-03-31 | $1.75 10-K · filed 2014-06-25 | ||||
| 2012-03-31 | $1.75 10-K · filed 2013-07-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |